World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
79
Citations
23954
World Ranking
4281
National Ranking
2091

Overview

Varsha Gandhi is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions to genetics, molecular biology, pathology and forensic medicine, hematology, and immunology. The core topics of their work include chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, acute lymphoblastic leukemia research, chronic myeloid leukemia treatments, biochemical and molecular research, immunodeficiency and autoimmune disorders, and acute myeloid leukemia research.

Frequent publication venues for their research include:

  • Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature
  • Blood
  • Blood Cancer Journal
  • Blood Advances
  • International Journal of Radiation Oncology*Biology*Physics

Among notable recent papers by Varsha Gandhi are:

  • Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia, 2021, JAMA Oncology
  • Ibrutinib combinations in CLL therapy: scientific rationale and clinical results, 2021, Blood Cancer Journal
  • AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia, 2020, Clinical Cancer Research
  • Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine, 2021, Journal of Hematology & Oncology
  • Targeting MCL-1 protein to treat cancer: opportunities and challenges, 2023, Frontiers in Oncology

Their frequent co-authors include Prithviraj Bose, William G. Wierda, Nitin Jain, Mary Ayres, and Michael J. Keating, reflecting collaborative work across their research topics.

Best Publications

  • An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

    Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny

  • Gemcitabine : metabolism, mechanisms of action, and self-potentiation

    W. Plunkett;Peng Huang;Yi-Zheng Xu;V. Heinemann

  • The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

    Sabine Ponader;Shih Shih Chen;Joseph J. Buggy;Kumudha Balakrishnan

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

    Varsha Gandhi;Elihu Estey;Michael J. Keating;William Plunkett

  • Preclinical characteristics of gemcitabine

    William Plunkett;Peng Huang;Varsha Gandhi

  • Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs.

    Yunyan Kuang;Yunyan Kuang;Kumudha Balakrishnan;Varsha Gandhi;Xiaohua Peng

  • Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

    Rong Chen;Michael J. Keating;Varsha V Gandhi;William K Plunkett

  • Cellular and Clinical Pharmacology of Fludarabine

    Varsha V Gandhi;William K Plunkett

  • B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

    Maite P. Quiroga;Kumudha Balakrishnan;Antonina V. Kurtova;Mariela Sivina

  • Pathways and mechanisms of venetoclax resistance

    Prithviraj Bose;Varsha V. Gandhi;Marina Y. Konopleva

  • Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

    Qingshan Yang;Prexy Modi;Terry Newcomb;Christophe Quéva

  • Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

    Fabiola Cervantes-Gomez;Betty Lamothe;Jennifer A. Woyach;William G Wierda

  • Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers

    Hagop M. Kantarjian;Varsha Gandhi;Peter Kozuch;Stefan H Faderl

  • Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

    Rong Chen;William G Wierda;Sherri Chubb;Rachael E. Hawtin

  • Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

    Lisa S Chen;Sanjeev Redkar;David Bearss;William G Wierda

  • Targeting the apoptosis pathway in hematologic malignancies

    Shadia Zaman;Rui Wang;Varsha Gandhi

  • Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies

    J. Kurtzberg;T.J. Ernst;M.J. Keating;V. Gandhi

  • Fludarabine : pharmacokinetics, mechanisms of action, and rationales for combination therapies

    W. Plunkett;Varsha Gandhi;Peng Huang;L. E. Robertson

Frequent Co-Authors

William Plunkett
William Plunkett The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry opens doors to a wide range of related fields, many of which offer flexible online study options. Students interested in understanding human movement and health might consider online kinesiology degrees, which focus on physical activity, sports science, and rehabilitation.

Healthcare professionals with a background in biological sciences can choose advanced, high-demand pathways. For instance, those interested in mental health nursing may look into pmhnp online programs, while experienced nurses seeking to become family nurse practitioners can pursue a post masters fnp certification. Both options provide specialized expertise and career mobility in healthcare settings.

Additionally, students fascinated by food science, wellness, or dietetics might explore an online nutritionist degree. These programs blend biological principles with practical skills in nutrition, opening up growing career opportunities in wellness and public health.

By leveraging these related online degrees, students and professionals can expand their knowledge, diversify their skill set, and align their education with in-demand career pathways in the life sciences and healthcare sectors.

Best Scientists Citing Varsha Gandhi

Trending Scientists

Recently Published Articles